Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Adlai NortyeANL -2.69%8 Debt-to-Equity is 0.12 as of Jun. 2026, which is at its 10-year median of 0.12. GuruFocus rates ANL with a GF Score™ of 8/100. The stock has 5 warning signs investors should review. Among 954 Biotechnology companies, Adlai Nortye ranks better than 56.6% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Adlai Nortye's Debt-to-Equity or its related term are showing as below:
ANL'
s Debt-to-Equity Range Over the Past 10 Years
Min: -3.17 Med: 0.12 Max: 5.63
Current: 0.12
During the past 5 years, the highest Debt-to-Equity Ratio of Adlai Nortye was 5.63. The lowest was -3.17. And the median was 0.12.
ANL's Debt-to-Equity is ranked better than 56.6% of 954
companies
in the Biotechnology industry
Industry Median: 0.16
vs ANL: 0.12
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Adlai Nortye Debt-to-Equity Related Terms
Adlai Nortye Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Adlai Nortye's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ANL vs REPL, SLDB, ANNX: Debt-to-Equity Comparison
For the Biotechnology subindustry, Adlai Nortye's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adlai Nortye Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Adlai Nortye's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Adlai Nortye's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adlai Nortye (ANL) has a Debt-to-Equity of 0.12 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Adlai Nortye and its competitors. This is near median its historical median of 0.12. According to the industry distribution chart, Adlai Nortye ranks #414 out of 954 companies in the Biotechnology industry, placing it in the top 43.4%.
Is Adlai Nortye's Debt-to-Equity too high?
Adlai Nortye's current Debt-to-Equity of 0.12 is near median its 10-year median of 0.12. The Biotechnology industry median Debt-to-Equity is 0.16. Adlai Nortye's value of 0.12 is 25% below this industry median. Based on the distribution chart, Adlai Nortye ranks #414 out of 954 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Adlai Nortye has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Adlai Nortye's Debt-to-Equity compare to REPL and SLDB?
According to the Biotechnology industry distribution chart, Adlai Nortye ranks #414 out of 954 companies for Debt-to-Equity. This puts Adlai Nortye in the upper half of its industry. The industry median Debt-to-Equity is 0.16. Adlai Nortye's value of 0.12 is 25% below this benchmark. While the company's 10-year median is 0.12 vs. the industry median of 0.16, Adlai Nortye has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Adlai Nortye's current Debt-to-Equity of 0.12 is 25% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Adlai Nortye and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Adlai Nortye's current Debt-to-Equity is 0.12, which is near median its own 10-year median of 0.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adlai Nortye stock overvalued right now?
Adlai Nortye (ANL) has a current Debt-to-Equity of 0.12. The current Debt-to-Equity is 0.12, which is near median its 10-year median of 0.12 and 25% below the Biotechnology industry median of 0.16. Adlai Nortye's overall GF Score™ is 8/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Adlai Nortye (ANL), the current Debt-to-Equity is 0.12 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.
8GF Score
Get the complete analysis for ANL
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ANL has been successfully added to your 
